Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the performance of the PANArray human papilloma virus (HPV) test, a PCR-based DNAmicroarray assay, in detecting HPV from patient samples and its concordance with the cobas 4800 HPV and Hybrid Capture 2(HC2) tests. Materials and Methods: The PANArray HPV, cobas 4800 HPV, and HC2 tests were performed on 504 cervical swab samples frompatients with atypical cells of undetermined significance at five hospitals. The samples that were interpreted as ‘HPV-other’ typepositive in the PANArray HPV test were confirmed by direct sequencing. Results: The concordance rates were 80.8% between the cobas 4800 HPV and PANArray HPV tests [κ=0.59, 95% confidence interval(CI) 0.52−0.66] and 80.2% (κ=0.6, 95% CI 0.55−0.68) between the HC2 and PANArray HPV tests. Among the 62 patients negativeon PANArray HPV (defined as the absence of high risk HPV), but positive on both cobas 4800 HPV and HC2 tests, 42 (67.7%) testedpositive for ‘HPV-other’ types on the PANArray HPV test, and 31 (50.0%) had gray zone results [relative light unit/control (RLU/CO), 1.4−9.25] in the HC2 test. Of the patients deemed positive by the PANArray HPV test, 43 tested positive for high-risk (HR)HPV in cobas 4800 HPV and HC 2 tests. Among them, 58.2% showed HR HPV, including HPV 16, by direct sequencing, of which25% had gray results. Conclusion: Results classified as ‘HPV-other’ type by the PANArray HPV test, or gray zone results by HC2 (RLU/CO ratio level1−10) should be carefully interpreted using comprehensive clinical information.
Abstract
Purpose: This study aimed to evaluate the performance of the PANArray human papilloma virus (HPV) test, a PCR-based DNAmicroarray assay, in detecting HPV from patient samples and its concordance with the cobas 4800 HPV and Hybrid Capture 2(HC2) tests. Materials and Methods: The PANArray HPV, cobas 4800 HPV, and HC2 tests were performed on 504 cervical swab samples frompatients with atypical cells of undetermined significance at five hospitals. The samples that were interpreted as ‘HPV-other’ typepositive in the PANArray HPV test were confirmed by direct sequencing. Results: The concordance rates were 80.8% between the cobas 4800 HPV and PANArray HPV tests [κ=0.59, 95% confidence interval(CI) 0.52−0.66] and 80.2% (κ=0.6, 95% CI 0.55−0.68) between the HC2 and PANArray HPV tests. Among the 62 patients negativeon PANArray HPV (defined as the absence of high risk HPV), but positive on both cobas 4800 HPV and HC2 tests, 42 (67.7%) testedpositive for ‘HPV-other’ types on the PANArray HPV test, and 31 (50.0%) had gray zone results [relative light unit/control (RLU/CO), 1.4−9.25] in the HC2 test. Of the patients deemed positive by the PANArray HPV test, 43 tested positive for high-risk (HR)HPV in cobas 4800 HPV and HC 2 tests. Among them, 58.2% showed HR HPV, including HPV 16, by direct sequencing, of which25% had gray results. Conclusion: Results classified as ‘HPV-other’ type by the PANArray HPV test, or gray zone results by HC2 (RLU/CO ratio level1−10) should be carefully interpreted using comprehensive clinical information.
참고문헌 (26)
- Ferlay J, "Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008", Int J Cancer, 127, pp.2893~2917 (2010)[DOI]
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2015", Cancer Research and Treatment, 47(2), pp.142~148 (2015), 대한암학회[DOI]
- 설현주, "Epidemiologic characteristics of cervical cancer in Korean women", Journal of Gynecologic Oncology, 25(1), pp.70~74 (2014), 대한부인종양학회
- Walboomers JM, "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide", J Pathol, 189, pp.12~19 (1999)[DOI]
- 소경아, "The Impact of High-Risk HPV Genotypes Other Than HPV 16", 18 on the Natural Course of Abnormal Cervical Cytology: A Korean HPV Cohort Study, 2016, pp.48(4), 1313~1320[DOI]
- Ki EY, "Comparison of the Cobas 4800 HPV test and the Seeplex HPV4A ACE with the hybrid capture 2 test", Int J Med Sci, 10, pp.119~123 (2013)[DOI]
- Agorastos T, "Primary screening for cervical cancer based on high-risk human papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to cytology", PLoS One, 10, pp.e0119755~ (2015)[DOI]
- Saslow D, "American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer", Am J Clin Pathol, 137, pp.516~542 (2012)[DOI]
- Castle PE, "Evaluation of a prototype real-time PCR assay for carcinogenic human papillomavirus (HPV) detection and simultaneous HPV genotype 16 (HPV16) and HPV18 genotyping", J Clin Microbiol, 47, pp.3344~3347 (2009)[DOI]
- Kovacic MB, "Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality", Cancer Res, 66, pp.10112~10119 (2006)[DOI]
- 민경진, "Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media", Journal of Gynecologic Oncology, 23(1), pp.5~10 (2012), 대한부인종양학회
- Wong AA, "Comparison of the hybrid capture 2 and cobas 4800 tests for detection of high-risk human papillomavirus in specimens collected in PreservCyt medium", J Clin Microbiol, 50, pp.25~29 (2012)[DOI]
- Castle PE, "Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study", Lancet Oncol, 12, pp.880~890 (2011)[DOI]
- Lindemann ML, "Analytical comparison of the cobas HPV Test with Hybrid Capture 2 for the detection of high-risk HPV genotypes", J Mol Diagn, 14, pp.65~70 (2012)[DOI]
- Schiffman M, "Human papillomavirus and cervical cancer", Lancet, 370, pp.890~907 (2007)[DOI]
- 여민경, "Clinical Significance of an HPV DNA Chip Test with Emphasis on HPV-16 and", or HPV-18 Detection in Korean Gynecological Patients, 2016, pp.50(4), 294~299[DOI]
- 성연은, "Can human papillomavirus (HPV) genotyping classify non-16", 18 high-risk HPV infection by risk stratification?, 2016, pp.27(6), 1~10[DOI]
- 소경아, "Human Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea", 대한암예방학회지, 21(2), pp.104~109 (2016), 대한암예방학회[DOI]
- Stoler MH, "High-risk human papillomavirus testing in women with ASC-US cytology: results from the ATHENA HPV study", Am J Clin Pathol, 135, pp.468~475 (2011)[DOI]
- Park Y, "Comparison of the Abbott RealTime High-Risk Human Papillomavirus (HPV), Roche Cobas HPV, and Hybrid Capture 2 assays to direct sequencing and genotyping of HPV DNA", J Clin Microbiol, 50, pp.2359~2365 (2012)[DOI]
- Federschneider JM, "The borderline or weakly positive Hybrid Capture II HPV test: a statistical and comparative (PCR) analysis", Am J Obstet Gynecol, 191, pp.757~761 (2004)[DOI]
- Ordi J, "Human papillomavirus load in Hybrid Capture II assay: does increasing the cutoff improve the test", Gynecol Oncol, 99, pp.313~319 (2005)[DOI]
- Peyton CL, "Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies", J Clin Microbiol, 36, pp.3248~3254 (1998)
- Carozzi FM, "Reproducibility of HPV DNA testing by hybrid capture 2 in a screening setting", Am J Clin Pathol, 124, pp.716~721 (2005)[DOI]
- Massad LS, "2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors", Obstet Gynecol, 121, pp.829~846 (2013)[DOI]